Ask AI
ProCE Banner Activity

PREFER-LA: Switch to LA CAB + RPV in People Living With HIV and Previous Adherence Challenges

Conference Coverage
Slideset

In this real-world observational study evaluating perspectives of people living with HIV who switched to LA CAB + RPV after previous challenges adhering to daily oral ART, 97.5% preferred the long-acting injectable regimen for alleviation of pill fatigue, improved convenience, and reduced stigma.

Released: October 24, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare